Why science creates value—and financing friction
Academic start-ups are the subject here, and the specific problem is why two ventures connected to scientific research can enter very different financing paths. To understand that difference, it is not enough to ask whether the technology is impressive. A useful judgment also requires separating the signal carried by the technology from the capabilities and relationships carried by the founding team, then locating the venture’s immediate constraint: time, technical proof, commercial competence, or investor access.
Two routes into the academic start-up category
The OECD study uses two related measures of academic entrepreneurship. Its primary measure, an academic-entrepreneur start-up, is a company with at least one founder who holds a PhD or doctoral degree. In the study’s sample of 81,318 start-ups, 8,065—9.9%—meet that definition. The measure is intentionally broad: it does not require the founder to have been employed by a university at the moment of founding, nor does it require the company to hold a patent derived from academic research.
The second measure starts with the company’s intellectual property rather than the founder. An academic-patent start-up has a patent filed before or within two years of foundation that is jointly applied for with a university, cites a university-filed patent, or cites scientific non-patent literature. The study identifies 3,190 such companies, of which 1,260 also have an academic founder. The overlap is substantial enough to show a connection, but small enough to make the distinction important.
These measures capture different routes from research to commercial activity. A doctoral founder may carry specialised knowledge, experimental habits, and access to academic colleagues into a company without filing a patent in the first two years. Such a venture may be commercialising tacit knowledge: know-how that matters to the product but is not fully represented by a formal intellectual-property asset. Conversely, a company may be founded by an experienced entrepreneur who licenses or otherwise uses university-derived technology without having a PhD founder. Its technical asset may be visibly linked to academic research even though its team does not carry the same academic imprint.
That difference changes what the outside world can evaluate. A founder’s academic background can signal technical depth, proximity to new knowledge, or the ability to understand a difficult problem. It does not by itself show that the team can recruit customers, negotiate partnerships, price a product, or raise a later round. A patent can make a technical claim more observable and give an investor something to assess, but it does not establish that a market exists or that the company can deliver at scale. The two signals answer different questions: who knows the science, and what technical asset can the company protect or commercialise?
It is useful to imagine the difference without turning either measure into a stereotype. One team might consist of researchers who understand a difficult biological process but are still testing whether hospitals will adopt a product built around it. Another might have a non-academic founder who has previously sold into that market and is now commercialising a university-originated patent. Both ventures are science-linked. The first may need time, laboratory resources, and help translating research into a buyer’s problem. The second may be able to present a more familiar commercial route, even if its technology remains technically demanding. The evidence does not say that the second team will succeed; it shows why the two teams should not be expected to face the same first financing conversation.
The distinction also matters for the financing path. If a team’s strongest evidence is a research capability, early support may need to create time and a prototype before an investor can judge the opportunity. If the venture already has a formal, defensible, and commercially relevant asset, that asset may broaden the set of financing options available at the outset. The OECD duration results point in this direction: academic founders reach grants and assistance faster, while start-ups identified by academic patents have faster access to several forms of financing, including equity. This is an association in the observed data, not proof that a patent alone causes faster investment. It does show why “academic” is not a single financing signal.
The two dimensions meet at two interfaces. The first is the research-to-product interface: scientific knowledge has to become a prototype, a measurable performance claim, or a product that a customer can evaluate. The second is the founder-to-capital interface: technical expertise has to be connected to business planning, industry relationships, and an explanation of how an investor might eventually realise a return. A university or research institution may help with facilities, intellectual property, and introductions, but it cannot guarantee demand. A founding team may control the development plan, but it cannot control an investor’s risk tolerance or the timing of a market. Financing friction appears when these interfaces are not ready at the same time.
The diagram represents an interface problem. Research knowledge must cross into a product that customers and investors can understand; founder expertise must connect with business and industry capabilities. Grants and assistance can help at either interface, but they do so differently. A grant can pay for experiments or development time. Assistance can add mentoring, facilities, training, and introductions. Neither result should be assumed automatically: the support is useful only insofar as it produces evidence or relationships that change the next financing conversation.
Where the financing friction comes from
Academic start-ups often work on technologies that are more complex, capital-intensive, and distant from market readiness than the typical early-stage investment can comfortably absorb. Their potential return may be large, but it arrives after a longer period during which investors bear technical, regulatory, adoption, and execution risks. That delay matters financially. More time before revenue or a liquidity event means more capital tied up and more opportunities for the underlying technology or market to change. It also makes valuation harder: a private investor must form a view about a distant outcome using evidence that is still incomplete.
The risk is transmitted through the financing structure. A grant is non-dilutive and does not normally require repayment, so the public or private grant-maker carries more of the early uncertainty while the founders retain ownership. Equity investors share in the upside if the company grows, but they accept the possibility that the investment becomes illiquid or worthless and may therefore demand evidence of a large commercial opportunity. Debt shifts the immediate obligation to the company: repayment and interest are due even when the technology has not yet produced reliable cash flow. Assistance may involve little direct money, but it can reduce the search and execution costs that prevent a team from reaching the next investor. The relevant question is not simply who supplies the largest amount; it is who bears which risk, and what evidence the instrument is expected to produce before the next decision.
The OECD data show why this is not only a matter of founder ambition. Academic founders are concentrated in fields where the development burden can be high. About one in four start-ups in Health, including biotechnology, has an academic founder. The share is about one in six in Energy, Resources and Sustainability, and about one in seven in Manufacturing. Information technology contains the largest absolute group of academic start-ups and has an academic-founder share of about 12%. These sectors also make heavy use of non-equity support, and grants account for the largest share of non-equity funding in the health, manufacturing, and energy-related groups.
This pattern should not be read as a country or sector ranking. The OECD sample covers 38 countries after its filters, and the observed series contains registration and data-collection lags. The useful point is more limited: where academic start-ups are common, their technical and capital requirements are often part of the sector’s normal economics. A grant-heavy early path may reflect the time needed to build a therapeutic, energy, or advanced manufacturing capability, not simply a preference for public money. At the same time, sector alone cannot identify the right instrument. Two health ventures may differ sharply in regulatory distance, customer access, and prototype maturity.
The founding team creates a second layer of friction. Academic start-ups have larger teams on average—2.8 founders compared with 1.7 for non-academic start-ups—but are less likely to include a founder with an MBA, 10% compared with 17%. Team size can increase the range of expertise available and can make it easier to divide demanding tasks. It is not the same as complementarity. Three founders with closely overlapping research backgrounds may still lack someone who can sell, negotiate, manage operations, or explain the business case to an investor. The OECD evidence does not show that adding an MBA would mechanically close the funding gap; it does show that business capability is a relevant observed distinction, especially when the venture must raise follow-on capital.
Social capital is just as important as formal skill. Academic researchers tend to have dense networks within universities and their scientific fields. Those networks can provide collaborators, facilities, early technical feedback, and credibility among specialists. They may not provide a direct route to industrial customers, experienced operators, angels, or venture capitalists. Private financing depends partly on the ability to find the right investors and persuade them that the team can convert technical progress into a return. When a venture lacks those relationships, the cost is not merely social discomfort. The founders may spend longer identifying investors, receive less useful commercial feedback, and reach the next financing round with weaker market evidence.
This is why scientific quality can produce a paradox. The OECD finds that academic entrepreneurs are more likely to hold patents, cite university patents, file jointly with universities, and cite scientific literature. Academic-research-linked patents are more general, radical, original, and likely to be classified as breakthroughs. Those properties indicate substantial innovation potential. They can also make the technology harder for a private investor to compare with familiar businesses or for an acquiring company to integrate. A promising invention is not yet a predictable business asset. More originality can increase eventual value while increasing the number of technical and commercial assumptions that must be tested first.
A practical financing diagnosis therefore starts with the bottleneck rather than the label. If the venture is primarily short of development time, non-dilutive funding may protect ownership while the team reaches a technical milestone. The relevant proof might be a working prototype, a reproducible performance result, or progress toward a required approval—not merely another research paper. If the key uncertainty is whether a product works in a real setting, material funding and access to facilities or pilot users may matter more than a larger pitch deck. The goal is to turn technical claims into evidence that an outsider can inspect.
If the technology is credible but the team cannot explain the buyer, route to market, or financial plan, assistance and commercial expertise may create more value than additional runway alone. In this case, the missing output is not another experiment but a clearer account of who pays, why adoption is plausible, and what operating capabilities the company must acquire. If the evidence exists but the founders cannot reach suitable investors, an intermediary with industry and investor networks may be the missing component. That support is valuable because it changes the search set and the quality of feedback, not because an introduction guarantees investment.
These are not four mutually exclusive stages. A health venture may need laboratory resources and regulatory planning at the same time; an energy venture may need a pilot customer before private capital will take its technical claims seriously. The point is to identify which constraint is currently binding and which one will become binding after it is relieved. A first instrument chosen for the present bottleneck can still be a poor choice if it leaves the next interface unprepared. For example, preserving ownership through a grant may be sensible while a prototype is immature, but the team should know what commercial evidence must exist before the grant ends and who can help obtain it.
That last consideration is what separates an academic start-up’s financing path from a simple search for the cheapest money. The technology, team, university, intermediary, public programme, investor, customer, and eventual buyer each control different pieces of the transition from research to business. A founder can control the development plan but not an investor’s risk tolerance. A university can provide facilities and introductions but not guarantee commercial demand. A grant can absorb some early financial risk but cannot by itself create an industry network. The financing path emerges from how these parts connect and from whether each round leaves the venture with stronger evidence, broader capability, and more than one plausible next route.
The next question is therefore concrete: when an academic project is still before formal company formation, what does a targeted public grant actually change? The German evidence on the EXIST–Business Startup Grant offers a rare opportunity to examine that first bridge directly, before later financing outcomes are allowed to obscure it.